| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8adf1aa119f2fa8c92dc31e5ef07b387 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502 |
| filingDate |
2013-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99f5ec7d3dfa77007276bb1f8f4b7524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d3d1792f252fa7975bae13f9d6e91b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6af15c144854b1f5362d3ea6ccf9ca5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3396d8447bee0e756e9128cf82b0f1de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1827dafd66b52def883141c77e8eb0fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce956c5d289f8a3dad4a373e020a8b6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_385623618a94909cd025dd9e456acb53 |
| publicationDate |
2014-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014066447-A1 |
| titleOfInvention |
Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one |
| abstract |
The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017025814-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016020901-A1 |
| priorityDate |
2008-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |